AlgoTherapeutix Receives Regulatory Approval to Initiate Clinical Development of ATX01
The Pharma Data
DECEMBER 14, 2020
The trial, which will explore the pharmacokinetics and safety of ATX01 in healthy volunteers, is due to start in January 2021. AlgoTherapeutix recently raised a 12M€ Series A that will fund the Phase 1 and 2 clinical development of ATX01. More information at www.algotx.com. View source version on businesswire.com: [link].
52 
Let's personalize your content